NVCT Nuvectis Pharma Inc

$NVCT Anyone have a theory about this stock price fall? I find the results very encouraging - great depth of response including some complete responses.

$NVCT Key Highlights Strong efficacy: A 40% response rate in high-grade glioma (HGG), including three complete responses among 20 patients. Exceptional response depth: 87.5% of HGG responders achieved greater than 80% tumor reduction. Activity after prior BRAF treatment: Two of three previously treated patients achieved deep partial responses exceeding 80% tumor reduction, remaining on therapy beyond 14 and 17 months. Encouraging survival: Median overall survival of 17.2 months and a 94.4% one-year survival rate in HGG. Favorable safety: Only 14.3% experienced grade ≥3 treatment-related adverse events, with no treatment discontinuations due to adverse events. Broader potential: An improved salt formulation has shown promising activity in non-CNS tumors, with larger clinical studies underway. Valuation Upside: Largely treated as a free call option, NXP200’s emerging clinical evidence should support a meaningful recognition of its value,.

$NVCT Truffle pigs post today: Key Highlights Strong efficacy: A 40% response rate in high-grade glioma (HGG), including three complete responses among 20 patients. Exceptional response depth: 87.5% of HGG responders achieved greater than 80% tumor reduction. Activity after prior BRAF treatment: Two of three previously treated patients achieved deep partial responses exceeding 80% tumor reduction, remaining on therapy beyond 14 and 17 months. Encouraging survival: Median overall survival of 17.2 months and a 94.4% one-year survival rate in HGG. Favorable safety: Only 14.3% experienced grade ≥3 treatment-related adverse events, with no treatment discontinuations due to adverse events. Broader potential: An improved salt formulation has shown promising activity in non-CNS tumors, with larger clinical studies underway. Valuation Upside: Largely treated as a free call option, NXP200’s emerging clinical evidence should support a meaningful recognition of its value, beyond the NXP100

$NVCT December company will be wrapping up NXP900 1b resistance combo Tagrisso. NVCT my biggest position and believing all 3 drugs will have value in the marketplace. Don't botch this trade, combo can make all other drugs and indications freerolls